{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:34:59Z","timestamp":1793133299501,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100020752","name":"Hebei University of Chinese Medicine","doi-asserted-by":"publisher","award":["XCXZZBS2026023"],"award-info":[{"award-number":["XCXZZBS2026023"]}],"id":[{"id":"10.13039\/501100020752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.anai.2026.09.736","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:22:43Z","timestamp":1790263363000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical remission in asthma"],"prefix":"10.1016","author":[{"given":"Zhiyue","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0872-6485","authenticated-orcid":false,"given":"Limei","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.anai.2026.09.736_bib0001","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/all.16382","article-title":"Biologics and airway remodeling in asthma: early, late, and potential preventive effects","volume":"80","author":"Varricchi","year":"2025","journal-title":"Allergy"},{"issue":"3S","key":"10.1016\/j.anai.2026.09.736_bib0002","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2025.05.035","article-title":"Asthma remission in the context of other immune-mediated diseases","volume":"156","author":"Smolen","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"10335","key":"10.1016\/j.anai.2026.09.736_bib0003","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(22)00331-2","article-title":"Disease-modifying anti-asthmatic drugs","volume":"399","author":"Lommatzsch","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2026.09.736_bib0004","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MCP.0000000000001068","article-title":"Remission in asthma","volume":"30","author":"Lommatzsch","year":"2024","journal-title":"Curr Opin Pulm Med"},{"issue":"176","key":"10.1016\/j.anai.2026.09.736_bib0005","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0181-2024","article-title":"Pro: clinical remission in asthma - implications for asthma management","volume":"34","author":"Principe","year":"2025","journal-title":"Eur Respir Rev"},{"issue":"176","key":"10.1016\/j.anai.2026.09.736_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0182-2024","article-title":"Con: clinical remission in asthma - not yet there","volume":"34","author":"Eggert","year":"2025","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.anai.2026.09.736_bib0007","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.09.736_bib0008","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society Workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.09.736_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00316-2024","article-title":"Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies","volume":"64","author":"Wechsler","year":"2024","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2026.09.736_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pccm.2025.05.001","article-title":"Achieving remission in severe asthma","volume":"3","author":"Thawanaphong","year":"2025","journal-title":"Chin Med J Pulm Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2026.09.736_bib0011","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with Benralizumab","volume":"39","author":"Menzies-Gow","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.anai.2026.09.736_bib0012","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)","volume":"59","author":"Moore","year":"2022","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.09.736_bib0013","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.09.736_bib0014","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/all.16590","article-title":"Clinical and biological remission with tezepelumab: the real-world response in severe uncontrolled asthma","volume":"80","author":"Gates","year":"2025","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.anai.2026.09.736_bib0015","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/biomedicines11041226","article-title":"T2-low asthma: a discussed but still orphan disease","volume":"11","author":"Peri","year":"2023","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.anai.2026.09.736_bib0016","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (Cascade): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.09.736_bib0017","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis","volume":"13","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"3S","key":"10.1016\/j.anai.2026.09.736_bib0018","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaci.2025.05.034","article-title":"Current data on biologics: evaluating clinical remission in asthma","volume":"156","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.09.736_bib0019","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2024.10.009","article-title":"Dupilumab induces long-term on-treatment clinical remission in patients with type 2 asthma","volume":"13","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.anai.2026.09.736_bib0020","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.anai.2026.09.736_bib0021","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2003.016246","article-title":"Childhood factors associated with asthma remission after 30 year follow up","volume":"59","author":"Vonk","year":"2004","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.anai.2026.09.736_bib0022","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jaci.2026.05.006","article-title":"One-year clinical remission with tezepelumab in severe asthma: TERESA single-arm prospective study","volume":"158","author":"Kan-O","year":"2026","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2026.09.736_bib0023","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Defining a severe asthma super-responder: findings from a Delphi process","volume":"9","author":"Upham","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2026.09.736_bib0024","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.anai.2026.09.736_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.107940","article-title":"The impact of blood eosinophil count and FeNO on Benralizumab effectiveness in clinical practice: an ORBE II subanalysis","volume":"237","author":"Garc\u00eda-Moguel","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2026.09.736_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107720","article-title":"Dupilumab responder types and predicting factors in patients with type 2 severe asthma: a real-world cohort study","volume":"231","author":"Bult","year":"2024","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.anai.2026.09.736_bib0027","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2026.09.736_bib0028","doi-asserted-by":"crossref","first-page":"00485","DOI":"10.1183\/23120541.00485-2022","article-title":"Precision medicine intervention in severe asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics","volume":"9","author":"Lee","year":"2023","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.anai.2026.09.736_bib0029","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/all.16425","article-title":"Early reduction of FeNO on anti-IL5 biologics is associated with clinical remission of severe asthma","volume":"80","author":"Soendergaard","year":"2025","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2026.09.736_bib0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaip.2024.10.041","article-title":"Early treatment response to mepolizumab predicts clinical remission in severe eosinophilic asthma","volume":"13","author":"Hamada","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2026.09.736_bib0031","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00782-2024","article-title":"Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma","volume":"65","author":"Hamada","year":"2025","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.09.736_bib0032","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chest.2025.04.011","article-title":"XALOC-1: clinical remission over 2 years with Benralizumab in severe eosinophilic asthma","volume":"168","author":"Pelaia","year":"2025","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.anai.2026.09.736_bib0033","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.anai.2026.09.736_bib0034","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK severe asthma registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2026.09.736_bib0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.23822\/EurAnnACI.1764-1489.318","article-title":"Variables predicting clinical remission among adults with severe asthma treated with biologic agents","volume":"56","author":"Ye\u015filkaya","year":"2024","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.09.736_bib0036","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3390\/biomedicines13040887","article-title":"Pathway to remission in severe asthma: clinical effectiveness and key predictors of success with Benralizumab therapy: a real-life study","volume":"13","author":"Damia\u0144ski","year":"2025","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.anai.2026.09.736_bib0037","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.3390\/biomedicines13102404","article-title":"Determinants of clinical remission in dupilumab-treated severe eosinophilic asthma: a real-world retrospective study","volume":"13","author":"Bonato","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.anai.2026.09.736_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.anai.2026.09.736_bib0039","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaip.2025.01.010","article-title":"Mucus plug score predicts clinical and pulmonary function response to biologic therapy in patients with severe asthma","volume":"13","author":"G\u00f6tschke","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2026.09.736_bib0040","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1164\/rccm.202310-1730OC","article-title":"Biomarker predictors of clinical efficacy of the anti-IgE biologic omalizumab in severe asthma in adults: results of the SoMOSA study","volume":"210","author":"Djukanovi\u0107","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.anai.2026.09.736_bib0041","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1016\/j.jaip.2025.08.027","article-title":"Observational analysis of biological remission as a treatment target for severe asthma: UK severe asthma registry","volume":"13","author":"McDowell","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2026.09.736_bib0042","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.anai.2022.10.018","article-title":"Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction","volume":"130","author":"Hanania","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.09.736_bib0043","doi-asserted-by":"crossref","first-page":"00204","DOI":"10.1183\/23120541.00204-2019","article-title":"Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma","volume":"6","author":"Castro","year":"2020","journal-title":"ERJ Open Res"},{"issue":"1","key":"10.1016\/j.anai.2026.09.736_bib0044","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.09.736_bib0045","article-title":"The effects of Benralizumab on lung volumes and airway resistance in severe eosinophilic asthma: a real-world study","volume":"16","author":"Madeira","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.anai.2026.09.736_bib0046","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaip.2021.09.023","article-title":"Anti-interleukin-5 therapy is associated with attenuated lung function decline in severe eosinophilic asthma patients from the Belgian severe asthma registry","volume":"10","author":"Graff","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2026.09.736_bib0047","first-page":"520","article-title":"Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma","volume":"83","author":"Hoshino","year":"2012","journal-title":"Respir Int Rev Thorac Dis"},{"issue":"2","key":"10.1016\/j.anai.2026.09.736_bib0048","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaci.2024.10.024","article-title":"Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype","volume":"155","author":"Domvri","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2026.09.736_bib0049","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1111\/all.16214","article-title":"Evaluation of dupilumab and Benralizumab on peripheral airway resistance and reactance","volume":"79","author":"Chan","year":"2024","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2026.09.736_bib0050","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2025.06.037","article-title":"Effect of dupilumab on small airways measured by airway oscillometry in VESTIGE","volume":"156","author":"Washko","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"4 Pt 1","key":"10.1016\/j.anai.2026.09.736_bib0051","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1164\/ajrccm.159.4.9806052","article-title":"Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL study group","volume":"159","author":"Sont","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2026.09.736_bib0052","unstructured":"Clinicaltrials.gov. REVErsing airway remodelling with tezepelumab: a protocol for a double-blind randomized controlled trial for patients with asthma. Accessed July 16, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05651841"},{"key":"10.1016\/j.anai.2026.09.736_bib0053","unstructured":"Clinicaltrials.gov. A Phase 4, multicenter, randomized, double-blind, parallel group, placebo controlled study to evaluate the effect of Benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Accessed July 16, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03953300"},{"key":"10.1016\/j.anai.2026.09.736_bib0054","unstructured":"Clinicaltrials.gov. A two-arm, placebo-controlled, randomized clinical trial to evaluate the effect of tezepelumab on airway structure and function in patients with uncontrolled moderate-to-severe asthma. Accessed July 16, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05280418"},{"key":"10.1016\/j.anai.2026.09.736_bib0055","unstructured":"Clinicaltrials.gov. REverse LuNg airway and vascular RemOdeling in asthma ReMission (ReNORM). Accessed July 16, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07174713"},{"key":"10.1016\/j.anai.2026.09.736_bib0056","unstructured":"Clinicaltrials.gov. Effect of Benralizumab on airway remodeling in asthma. Accessed July 16, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04365205"},{"key":"10.1016\/j.anai.2026.09.736_bib0057","unstructured":"Clinicaltrials.gov. BURAN: effects of Benralizumab on airway dynamics in severe eosinophilic asthma using functional respiratory imaging parameters. Accessed July 16, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05552508"},{"issue":"25","key":"10.1016\/j.anai.2026.09.736_bib0058","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of Benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.anai.2026.09.736_bib0059","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.anai.2026.09.736_bib0060","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"10423","key":"10.1016\/j.anai.2026.09.736_bib0061","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance ICSs in patients with severe eosinophilic asthma treated with Benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.anai.2026.09.736_bib0062","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2030880","article-title":"Risankizumab in severe asthma - a phase 2a, placebo-controlled trial","volume":"385","author":"Brightling","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.anai.2026.09.736_bib0063","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of Brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"10095","key":"10.1016\/j.anai.2026.09.736_bib0064","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.anai.2026.09.736_bib0065","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMoa1613125","article-title":"KIT inhibition by imatinib in patients with severe refractory asthma","volume":"376","author":"Cahill","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.09.736_bib0066","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626011981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626011981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:24:28Z","timestamp":1793132668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626011981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":66,"alternative-id":["S1081120626011981"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.09.736","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical remission in asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.09.736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}